COMPARISON OF REDUCTIONS IN MONTHLY MIGRAINE DAYS BETWEEN NEW SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS (GEPANTS) AND MONOCLONAL ANTIBODIES TARGETING CGRP/CGRP RECEPTOR